New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
07:03 EDTAUXLAuxilium sees FY13 revenue $325M-$355M, consensus $342.3M
Sees FY13 Testim revenue $250M-$265M; Sees FY13 U.S. Xiaflex revenue $65M-$75M; Sees ex.U.S. Xiaflex revenue $10M-$15M; Sees FY13 non-GAAP net income $18M-$23M
News For AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent AUXL news | >>
September 22, 2014
07:10 EDTAUXLQLT Inc. says, Auxilium determines Endo proposal not superior
07:02 EDTAUXLAuxilium board determines QLT Inc.'s agreement superior to Endo proposal
Auxilium (AUXL) announced that its board has reviewed the unsolicited, non-binding and conditional proposal from Endo (ENDP) and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under the terms of its existing merger agreement with QLT Inc. (QLTI) and has unanimously reaffirmed its recommendation that Auxilium's stockholders vote in favor of the adoption of such merger agreement. In addition, the board has determined that Endo's proposal significantly undervalues Auxilium. However, under the terms of the merger agreement with QLT, Auxilium maintains the right to engage in discussions with Endo and other third parties, subject to certain conditions in the merger agreement. In unanimously reaffirming its recommendation that Auxilium's stockholders vote in favor of the adoption of the existing merger agreement with QLT, the board confirmed that it is not withdrawing, modifying, withholding, changing or qualifying its recommendation with respect to such merger agreement, or proposing to do so.
06:11 EDTAUXLAuxilium downgraded to Hold from Buy at Stifel
Stifel downgrade Auxilium (AUXL) following the bid by Enco (ENDO) and said shares reflect a potential higher offer.
06:09 EDTAUXLStocks with implied volatility below IV index mean; AUXL YELP
Subscribe for More Information
September 19, 2014
16:24 EDTAUXLStocks rise after Fed keeps pledge for 'considerable time' before rate hike
Subscribe for More Information
10:28 EDTAUXLOptions with decreasing implied volatility
Subscribe for More Information
10:06 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:22 EDTAUXLAuxilium downgraded to Neutral from Buy at UBS
Subscribe for More Information
September 18, 2014
20:23 EDTAUXLAuxilium downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Auxilium (AUXL) to Neutral citing a balanced risk/reward following the post-Endo (ENDP) takeover bid rally. The firm raised its price target for shares to $31 from $28.
16:27 EDTAUXLOn The Fly: Closing Wrap
Subscribe for More Information
16:20 EDTAUXLBioSpecifics says data suggests support for potential label expansion of XIAFLEX
Subscribe for More Information
12:45 EDTAUXLOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTAUXLRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:00 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:59 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:50 EDTAUXLEndo Auxilium deal would be disappointing over longer term, says Cantor
Subscribe for More Information
07:24 EDTAUXLAmerican Society for Surgery of the Hand to hold annual meeting
69th Annual Meeting of ASSH to be held in Boston on September 18-20.
07:02 EDTAUXLAuxilium presents XIAFLEX data from MULTICORD Phase 3b study
Subscribe for More Information
06:10 EDTAUXLFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
06:05 EDTAUXLVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
1 | 2 | all recent AUXL news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use